Chat with us, powered by LiveChat

Chapter 17: Use of Lhasa Limited Products for the In Silico Prediction of Drug Toxicity

Burns MJ; Foster RS; Hemingway R; Kocks G; Macmillan DS; Ponting DJ; Shannon-Little AL; Tennant RE; Tidmarsh J; Yeo D;

Chapter 17 in In Silico Methods for Predicting Drug Toxicity: Emilio Benfenati

“This fully updated book explores all-new and revised protocols involving the use of in silico models, particularly with regard to pharmaceuticals. Divided into five sections, the volume covers the modeling of pharmaceuticals in the body, toxicity data for modeling purposes, in silico models for multiple endpoints, a number of platforms for evaluating pharmaceuticals, as well as an exploration of challenges, both scientific and sociological. Written for the highly successful Methods in Molecular Biology series, chapters include the kind of detail and implementation advice necessary for successful results.

Authoritative and comprehensive, In Silico Methods for Predicting Drug Toxicity, Second Edition aims to guide the reader through the correct procedures needed to harness in silico models, a field which now touches a wide variety of research specialties.”

Chapter 17: Use of Lhasa Limited Products for the In Silico Prediction of Drug Toxicity

“A changing regulatory environment and the drive for the Replacement, Reduction and Refinement (the 3Rs) of animal testing have led both to increased acceptance of in silico predictions and a desire for the sharing of data to reduce duplicate testing. The combination of these factors has led to Lhasa Limited providing a suite of products and coordinating numerous data-sharing consortia that do indeed facilitate a significant reduction in the testing burden that companies would otherwise be laboring under. Many of these products and consortia can be organized into workflows for specific regulatory use cases, and it is these that will be used to frame the narrative in this chapter.”

Purchase the chapter on SpringerLink, using the button below.